Amgen, Merck, Roche get in on Syapse’s $30M round

Syapse's precision medicine software is already in use at 12 health systems.

Syapse picked up $30 million in series D financing, funds it will use to bring its oncology precision medicine software to more healthcare providers.

In addition to its oncology software platform, which enables caregivers in large health systems to practice precision medicine consistently, Syapse offers a data-sharing network. This provides physicians across the country with real-world data around treatments and outcomes, giving them more evidence on which to base treatment decisions for their patients.

More than 1,000 oncologists at 12 major health systems are already using the software, the San Francisco Business Times reported.


Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

RELATED: Donald Trump’s healthcare budget outlines FDA, NIH cuts

Amgen Ventures, Medidata Solutions, Merck Global Health Innovation Fund and Roche Venture Fund joined the company’s existing backers in the round, according to a statement. The latter group includes Ascension Ventures, GE Ventures and Intermountain Healthcare Innovation Fund.

Specifically, the San Francisco-based company will use the funds to expand its operations team and offer its precision medicine software at more community health systems. It will also enable Syapse’s customers to increase patient access to clinical trials.

RELATED: VA to use IBM's Watson to ramp up cancer precision medicine

"Precision medicine is transforming cancer care, and to deliver it to patients across the country we need to bring together the many stakeholders across industries," said Syapse CEO Ken Tarkoff. "This funding round does exactly that—helping Syapse and healthcare providers implement large-scale precision oncology programs by uniting a world-class group of healthcare, oncology, technology, and life science leaders.”

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

The FDA approved a new device for people suffering from advanced heart failure who are not able to receive treatment from other devices.